Loading...
XNAS
FGEN
Market cap34mUSD
Dec 05, Last price  
8.42USD
1D
2.06%
1Q
-30.41%
Jan 2017
-60.65%
IPO
-64.64%
Name

FibroGen Inc

Chart & Performance

D1W1MN
XNAS:FGEN chart
P/E
—
P/S
1.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.92%
Rev. gr., 5y
-35.07%
Revenues
30m
-79.95%
65,933,000102,170,000137,601,000180,828,000179,577,000125,668,000212,958,000256,577,000176,319,000235,309,000140,734,000147,752,00029,621,000
Net income
-48m
L-83.26%
-32,571,000-14,943,000-59,504,000-85,779,000-61,680,000-126,203,000-86,420,000-76,970,000-189,291,000-291,030,000-295,227,000-284,232,000-47,579,000
CFO
-138m
L-56.19%
-5,605,00025,918,00022,414,000-18,571,0007,108,000-66,513,000-76,144,000-78,705,00081,602,000-82,232,000-145,933,000-315,021,000-137,999,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
URL
https://www.fibrogen.com/
IPO date
Nov 14, 2014
Employees
592
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT